/

Società

Ad

Non verificato

Adcendo

Di cosa scriviamo

BiologiaEconomiaFarmaceuticaFinanzaSanità

8 comunicati stampa

Guarda tutti i comunicati

Press Release cover image

20/04/2026

Salute

Fitness

Medicina - Varie

Ecologia/Salute ambientale

Agricoltura

Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates

Fonte

Emittente

1.00

0

Press Release cover image

14/04/2026

Salute

Fitness

Economia

Medicina - Varie

Ecologia/Salute ambientale

Agricoltura

Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline

Fonte

Emittente

1.00

0

23/04/2025

Farmaceutica

Sanità

Finanza

Biologia

Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Fonte

Emittente

1.00

0

01/04/2025

Farmaceutica

Sanità

Economia

Management

Organizzazione Aziendale

Biologia

Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team

Fonte

Emittente

1.00

0

26/02/2025

Farmaceutica

Sanità

Biologia

Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02

Fonte

Emittente

1.00

0

Press Release cover image

25/11/2024

Farmaceutica

Sanità

Finanza

Banca

Mutui

Risparmio/Affari personali

Leasing

Gestione dei titoli obbligazionari

Fondi di investimento

Euro-obbligazioni

Biologia

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline

Fonte

Emittente

1.00

0

08/10/2024

Farmaceutica

Sanità

Biologia

Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)

Fonte

Emittente

1.00

0

20/08/2024

Farmaceutica

Sanità

Economia

Brevetti, marchi e copyright

Biologia

Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0